ReviewDrugs2007
Clostridium difficile-associated disease: changing epidemiology and implications for management.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 89 citations in OpenAlex.
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2026Article
- Association Between Antimicrobials and Pump Proton Inhibitors Consumption with the Incidence of NosocomialAntibiotics (Basel, Switzerland) · 2025Article
- Pancreatic disease patients are at higher risk forGut pathogens · 2019Article
- Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).Intestinal research · 2018Review
- Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong.Scientific reports · 2017Article
- Current advances related to Clostridium difficile infection.The Indian journal of medical research · 2015Review
- Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015Article
- Clinical update for the diagnosis and treatment of Clostridium difficile infection.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- Antimicrobial-resistant strains of Clostridium difficile from North America.Antimicrobial agents and chemotherapy · 2012Article
- Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.Case reports in gastroenterology · 2010Article
- Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?Bone marrow transplantation · 2008Review
- New advances in the treatment of Clostridium difficile infection (CDI).Therapeutics and clinical risk management · 2008Article
- Clostridium difficile infection: a critical overview.Current infectious disease reports · 2008Article
- An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?Critical care (London, England) · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile-associated disease (CDAD) is increasingly being reported in many regions throughout the world. The reasons for this are unknown, are likely to be multifactorial, and are the subject of several current investigations. In addition to the upsurge in frequency of CDAD, an increased rate of relapse/recurrence, disease severity and refractoriness to traditional treatment have also been noted. Moreover, severe disease has been reported in non-traditional hosts (e.g. younger age, seemingly healthy, non-institutionalised individuals residing in the community, and some without apparent antimicrobial exposure). A previously uncommon and more virulent strain of C. difficile has been reported at the centre of multiple transcontinental outbreaks. The appearance of this more virulent strain, in association with certain environmental and antimicrobial exposure factors, may be combining to create the 'perfect storm'. It is human nature to be reactive; however, the successful control of C. difficile will require healthcare systems (including administrators, and leadership within several departments such as environmental services, infection control, infectious diseases, gastroenterology, surgery, microbiology and nursing), clinicians, long-term care and rehabilitation facilities, and patients themselves to be proactive in a collaborative effort. Guidelines for the management of CDAD were last published over a decade ago, with the next iteration due in the fall (autumn) of 2007. Several newer therapies are under investigation but it is unclear whether they will be superior to current treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.